CDK9-IN-7

SKU: orb1710103

Description

CDK9-IN-7 is a potent and selective oral inhibitor of the CDK9/cyclin T complex with an IC50 of 11 nM, demonstrating significant selectivity over CDK4/6. This compound is a valuable chemical probe for researching transcription regulation in oncology, particularly in studies of cancer cell proliferation and apoptosis, both in vitro and in vivo.

Research Area

Cell Biology, Epigenetics & Chromatin

Key Properties

• CAS Number: 2369981-71-3
• MW: 547.71
• Purity: 98.19% (May vary between batches)
• Formula: C₂₉H₃₇N₇O₂S
• SMILES: C(N(C)C)(=O)C=1N(C=2C(C1)=CN=C(NC3=CC=C(NC(CCCCCCCN=C=S)=O)C=C3)N2)C4CCCC4
• Target: CDK,Apoptosis
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.83 mM);DMSO:10 mg/mL (18.26 mM)

Bioactivity

• Target IC50:
  CDK9-CyclinT1:11 nM|CDK4-CyclinD:148 nM|CDK6-CyclinD:145 nM
• In Vitro:
  CDK9-IN-7 (compound 21e) displays exceptional potency against NSCLC cell lines, especially A549 and H1299 with IC50 values less than 0.5 µM. In the drug-resistant NSCLC cell line H1975, CDK9-IN-7 also exhibits good inhibition potency (IC50: 0.837 µM).
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CDK9IN7, CDK-9-IN-7, CDK9-IN-7, CDK9/cyclin T1, CDK9/cyclinT1, CDK9 IN 7, CDK6/cyclinD, CDK4/CyclinD, CDK4/cyclin D

Compound Identifiers

PubChem CID

138911336